2 min read
Home >
Blog
Blog | Veristat, The Science-First CRO
Gain the latest insights and trends in clinical trials, patient recruitment, data analysis, adaptive design, regulatory submissions and approvals.
Sign Up Today
Full-Service
1 min read
Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial
June 22, 2023
Learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas of this full-service phase II cancer trial. Collaborative efforts led to the sponsor decided not to close the Phase II study upon the...
Bold Thinking that Delivers Results for RNA Therapies
March 24, 2023
Current advances in RNA-based therapies hold substantial promise in treating and preventing many human diseases and disorders through curing the disease, rather than treating the symptomology like traditional therapeutics.
2 min read
On-Demand Webinar: Decentralized Trial Solutions for Complex Clinical Trials
January 31, 2023
Decentralized clinical trials (DCTs) are becoming increasingly popular to optimize patient engagement and retention. At the same time, making DCTs a successful reality for the most complex studies is considered difficult given the many logistical and...
5 min read
Laying the Groundwork to Measure the Impact of Decentralized Clinical Trials (DCTs)
January 9, 2023
The Tufts CSDD Roundtable took place in November, and on behalf of Veristat, I was honored to participate in this invite-only program. It is part of our company’s DNA to stay ahead of the driving forces in the industry so that we can best serve as a...
1 min read
Is it Possible to Gain Regulatory Approval Following a Single-Arm Study?
April 26, 2022
In this case study example - yes.
Veristat developed a thorough regulatory submission strategy and novel efficacy endpoint for the treatment of an ultra-rare and aggressive hematologic malignancy that led to FDA and EMA approval following a single-arm...
4 min read
Planning the Way Forward in Neurodegenerative Disease Studies
June 16, 2021
Clinical trials involving gene therapies for the treatment of Central Nervous System (CNS) indications are some of the more complex in the field of gene and cell therapy (G&CT) development. During the lockdown, the Food and Drug Administration (FDA)...